AndrewMEvensDO, MBA, MSc

PubMed

• 83 citations
  Treatment of Hodgkin lymphoma: the past, present, and future
  Andrew M. Evens, Martin Hutchings, Volker Diehl
  Nature Clinical Practice. Oncology. 2008-09-01
• 113 citations
  Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma
  Sally E. Trabucco, Rachel M. Gerstein, Andrew M. Evens, James E. Bradner, Leonard D. Shultz
  Clinical Cancer Research. 2015-01-01
• 663 citations
  Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports ...
  Kenneth R. Carson, Andrew M. Evens, Elizabeth A. Richey, Thomas M. Habermann, Daniele Focosi
  Blood. 2009-05-14

Journal Articles

• FDG-PET Imaging for Hodgkin Lymphoma: Current Use and Future Applications  
  Kostakoglu L and Evens AM, Clinical Advances in Hematology & Oncology, 1/1/2014
• A Phase I/II Trial of Bortezomib Combined Concurrently with Gemcitabine for Relapsed or Refractory DLBCL and Peripheral T-cell Lymphomas  
  Evens AM, Rosen ST, Helenowski I, Kline J, Larsen A, Colvin J, Winter JN, Van Besien KM, Gordon LI, Smith SM, British Journal of Haematology, 8/8/2013
• Intergroup Study Evaluates Outcomes of Elderly vs Younger Patients Treated for Advanced Hodgkin Lymphoma  
  Evens AM, ASCO Post, 7/15/2011
• Novel Targeted Agents for the Treatment of Hodgkin Lymphoma  
  Feliciano J, Moll MZ, Evens AM, CML – Leukemia & Lymphoma, 1/1/2010
• Reply to D Dierickx et al  
  Evens AM, Smith SM, Journal of Clinical Oncology, 1/1/2010
• Systemic treatment of Hodgkin lymphoma  
  Evens AM, Hutchings M, Diehl V, PPO Updates, Principles & Practice of Oncology, 1/1/2007
• Update on approaches to the treatment of follicular lymphoma  
  Evens AM, Gordon LI, Rosen ST, Winter JN, Oncology Special Edition, 1/1/2006
• A Patient With Relapsed Rituximab-Refractory Follicular Lymphoma Treated With Motexafin Gadolinium and Yttrium-90 Ibritumomab Tiuxetan  
  Rizvi MA, Spies SM, Evens AM, Case Studies in Lymphoma, 1/1/2005
• Join now to see all

Books/Book Chapters

• Conn's Current Therapy. 
  Chapter: Non Hodgkin’s Lymphoma. 
  Andrew M. EvensEditors: Bope & Kellerman.Edition 64th,2011
• A Multidisciplinary Approach. 
  Chapter: Non Hodgkin’s Lymphoma. 
  Andrew M. Evens, Jane N. Winter, Leo I. Gordon, Brian C.-H. Chiu, Richard Tsang, Steven T. RosenEditors: Haller D, Wagman LD, Camphausen KA, Hoskins WJ.Edition 14th,2011
• Adult Acute Lymphocytic Leukemia: Biology and Treatment. 
  Chapter: Burkitt Lymphoma and Leukemia. 
  Kevin A. David, Mark Roberts, LoAnn C. Peterson, and Andrew M. EvensEditors: Advani A and Lazurus H.Humana Press2010
• Management of Hematologic Malignancies. 
  Chapter: Hodgkin Lymphoma: Epidemiology, Diagnosis, and Treatment. 
  Page 1375 - 1507Vose JM, Kantarjian HM, O’Brien SEditors: Vose JM, Kantarjian HM, O’Brien S.2010
• A Multidisciplinary Approach. 
  Chapter: Non-Hodgkin lymphoma. 
  Andrew M. Evens, Jane N. Winter, Leo I. Gordon, Brian C.-H. Chiu, Richard Tsang, Steven T. RosenEditors: Haller D, Wagman LD, Camphausen KA, Hoskins WJ.Edition 13th,2010
• Lymphoma. 
  Chapter: T-cell lymphoma. 
  Page 215 - 232Muhajid Rizvi, Andrew M. Evens, Beverly P. Nelson, Steven T. RosenEditors: Marcus R, Sweetenham JW, Williams ME.CambridgeEdition 1st,2007
• Handbook of Cancer Chemotherapy. 
  Chapter: Acute Leukemias. 
  Page 411 - 459Andrew M. Evens and Martin S. TallmanEditors: Skeel RT.Lippincott Williams & Wilkins, Baltimore, MDEdition 6th,2003
• Cancer Management: A Multidisciplinary Approach. 
  Chapter: Non-Hodgkin’s Lymphoma. 
  Page 697 - 748Steven T. Rosen, Jane N. Winter, Leo I. Gordon, Andrew M. Evens, and Nicos NicolaouEditors: Pazdur, R, Coia LR, Hoskins WJ, Wagman LD.Edition 7th,2003
• Handbook of Chemotherapy. 
  Chapter: Adjuvant Chemotherapy. 
  Page 48 - 68Andrew M. Evens and Jacob D. BitranEditors: Perry MC.Lippincott Williams & Wilkins, Baltimore, MD2001
• Join now to see all

Abstracts/Posters

• The Novel 2nd Generation Proteasome Inhibitor MLN9708 Induces Redox- and MAPK-Dependent Cell Death in Hodgkin Lymphoma Cell and T-cell Lymphoma Cell Lines and Human Ly...
  Dashnamoorthy R, Kandela I, Bhalla S, Zaretsky I, Galloway J, Mazar A, Evens AM, Ninth International Symposium on Hodgkin’s Lymphoma, Cologne, Germany, 10/1/2013
• A multicenter phase II trial of rituximab (R) combined with bortezomib (B) therapy for untreated "high tumor burden" (HTB) indolent non-hodgkin lymphoma (i-NHL).
  Evens AM, Smith MR, Lossos IS, Winter JW, Cohen AD, Rosen ST, Gordon LI, 12th International Conference on Malignant Lymphoma (12-ICML), Lugano, Switzerland, 6/19/2013
• The Influence of Lifestyle Factors On Expression of Tumor-Related Microenvironment T-Cells and Impact On Survival of Follicular Lymphoma (FL).
  Evens AM, Chadburn A, Ollberding NJ, Dave SS, Aschebrook-Kilfoy B, Smith SM, Weisenburger D, Chiu C-H, 12th International Conference on Malignant Lymphoma (12-ICML), Lugano, Switzerland, 6/19/2013
• Results of a Phase 2 Multicenter Study of the Addition of Rituximab (R) to CODOX-M/IVAC for Untreated Burkitt’s Lymphoma (BL): Impact of Plasma and Cerebrospinal Fluid...
  Evens AM, Islam N, Carson KR, Browning V, Nabhan C, Jovanovic B, Barr PM, Caimi PF, Helenowski I, Gregory SA, Kolesar J, Gordon LI, 12th International Conference on Malignant Lymphoma (12-ICML), Lugano, Switzerland, 6/19/2013
• A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging: U.S. Intergroup S0816.
  Press OW, LeBlanc M, Rimsza LM, Schoder H, Friedberg JW, Li H, Bartlett H, LaCasce A, Sweetenham J, Evens AM, et al, 12th International Conference on Malignant Lymphoma (12-ICML), Lugano, Switzerland, 6/19/2013
• The Novel 2nd Generation Proteasome Inhibitor MLN9708 Induces Redox and MAPK-Dependent Cell Death in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cell Lines and Hum...
  R Dashnamoorthy and AM Evens, 12th International Conference on Malignant Lymphoma (12-ICML), Lugano, Switzerland, 6/19/2013
• The Histone Deacetylase Inhibitor (HDACi) Abexinostat): Significant Activity in Relapsed/Refractory Follicular Lymphoma (FL).
  AM Evens, et al, 12th International Conference on Malignant Lymphoma (12-ICML), Lugano, Switzerland, 6/19/2013
• Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicent...
  AM Evens et al, Blood (ASH Annual Meeting Abstracts), 1/1/2013
• The Influence Of Lifestyle Factors On Tumor-Related Markers and The Microenvironment In Follicular Lymphoma (FL): Novel Interactions and Collective Impact On Survival.
  Evens AM, Ollberding NJ, Chadburn A, Smith SM, Weisenburger DD, and Chiu BCH, Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Multiple Myeloma and Plasmactyoma-Like Post-Transplant Lymphoproliferative Disorders (PTLD): Examination Of Outcomes and Prognostication In The Modern Era.
  Rosenberg A, Ruthazer R, Paulus JK, Evens AM, and Klein AK, Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Pancreatitis In Patients Treated With Brentuximab Vedotin: A Previously Unrecognized Serious Adverse Event.
  Ghandi M, Evens AM, Fenske TS, Hamlin P, Coiffier B, Engert A, Moskowitz AJ, Ghosh N, Petrich AM, Lomasney J, Chadburn A, Wood GS, Salva K, Trifilio SM, Raisch DW, Wes..., Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Evaluation Of Potency and The Associated Biology Of The Investigational Proteasome Inhibitor, Ixazomib: Redox, Autophagic, and MAPK-Dependent Cell Death In T-Cell Lymp...
  Dashnamoorthy R, Kandela I, Bhalla S, Mazar A, Evens AM, Blood (ASH Annual Meeting Abstracts), 1/1/2013
• A Multicenter Phase II Study Of Bortezomib (VELCADE(R)) Combined With Rituximab For Untreated High Tumor Burden (HTB) Indolent Non-Hodgkin Lymphoma (NHL): Long-Term Fo...
  Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, Rosen ST, Gordon LI, Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Impact Of Induction Regimen and Consolidative Stem Cell Transplantation In Patients With Double Hit Lymphoma (DHL): A Large Multicenter Retrospective.
  Ghandi M, Petrich AM, Cassaday RD, Press OW, Shah K, Whyman J, Lansigan F, Zelenetz AD, Shah N, Fenske TS, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Karmali R, Meli..., Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Whole Genome and Exome Sequencing Defines The Genetic Landscape Of Hepatosplenic T-Cell Lymphoma.
  Scotland P, Gaulard P, Love CL, Fataccioli V, Travert M, De Leval L, Weisenburger DD, Czader M, Parihar M, Nair R, Sengar M, Beaven AW, Crow JH, Miles RR, Gordon LI, C..., Blood (ASH Annual Meeting Abstracts), 1/1/2013
• A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral...
  Advani R, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza FR, Carson KR, Evens AM, Foss FM, Horwitz SM, Pro B, Pinter-Brown L, Smith SM, Shustov AR, Savage KJ, Vose JM, Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Darinaparsin in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cells Lines and SCID Xenograft Mouse Models: Single-Agent Activity and Synergistic Cell Death Combined ...
  Dashnamoorthy R, Bhalla S, Crombie J, Kandela I, Mazar A, Evens AM, Blood (ASH Annual Meeting Abstracts), 12/1/2012
• Influence of Lifestyle Factors on Expression of Tumor-Related Microenvironment T-Cells and Impact on Survival of Follicular Lymphoma (FL).
  Evens AM, Chadburn A, Ollberding NJ, Dave SS, Aschebrook-Kilfoy B, Smith SM, Weisenburger DD, Chiu BC-H, Blood (ASH Annual Meeting Abstracts), 12/1/2012
• A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE (R)) Therapy for Untreated "High Tumor Burden" Indolent Non-Hodgkin Lymphoma (NHL).
  Evens AM, Smith MR, Lossos IS, Jovanovic B, Cohen A, Winter JN, Rosen ST, Gordon LI, Blood (ASH Annual Meeting Abstracts), 12/1/2012
• Primary Breast Diffuse Large B-Cell Lymphoma: A Distinct Clinical Entity.
  Salzeberg MP, Maragulia JC, Press OW, Habermann TM, Vose JM, Bast M, Advani RH, Evens AM, Islam N, Leonard JP, Martin P, Hosein PJ, Zelenetz AD, Lossos IS, Blood (ASH Annual Meeting Abstracts), 12/1/2012
• Fatty Acid Metabolism in Diffuse Large B-Cell Lymphoma (DLBCL): Interaction with Oncogenic Cell Signaling Pathways and the Identification of a Novel Treatment Paradigm.
  Dashnamoorthy R, Lansigan F, Davis WL III, Kuemmerle N, Kinlaw WB III, Evens AM, Blood (ASH Annual Meeting Abstracts), 12/1/2012
• The Impact of Race, Age, and Sex in Follicular Lymphoma (FL): A Comprehensive SEER Analysis in the Pre- and Post-Rituximab Eras.
  Nabhan C, Aschebrook-Kilfoy B, Chiu C-H, Kruczek K, Patel P, Smith SM, Evens AM, Blood (ASH Annual Meeting Abstracts), 12/1/2012
• The Impact of Race, Age, and Sex in Chronic Lymphocytic Leukemia (CLL): A Comprehensive SEER Analysis in the Pre and Post Rituximab (R) Eras.
  Nabhan C, Aschebrook-Kilfoy B, Evens AM, Chiu C-H, Smith SM, Shanafelt TD, Kay NE, Blood (ASH Annual Meeting Abstracts), 12/1/2012
• A Phase 2 Clinical Trial Adding Rituximab to CODOX-M/IVAC for Untreated Burkitts Lymphoma: Correlative Analysis of Serum and CSF Rituximab Levels.
  Evens AM, Islam N, Carson KR, Browning V, Nabhan C, Jovanovic B, Barr PM, Caimi PF, Helenowski I, Gregory SA, Kolesar J, Gordon LI, Blood (ASH Annual Meeting Abstracts), 12/1/2012
• Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.
  Evens AM, Feldman T, Kroll A, Muffly LS, Winer E, Flowers C, Lansigan F, Nabhan C, Nastoupil L, Kim A, Li X, Waksmundzki K, Lam D, Draper JT, Meilleur A, Nath R, Cygan..., Blood (ASH Annual Meeting Abstracts), 12/1/2012
• Join now to see all

Lectures

• A Phase II Studyof Sequential Pembrolizumab (PEM) Followed By AVD for Frontline Treatment of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following PEM Monot... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Systems Biology Analyses to Delineate Mechanisms of Anti-CD20 Antibody Resistance in Non-Hodgkin Lymphoma (NHL): Influence of BCR Signaling and the Critical Importance... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E0, the Bortezomib Ind... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Development and Validation of an Electronic Health Record (EHR)-Based Algorithm for Identifying Treatment Failure in Newly Diagnosed Hodgkin Lymphoma (HL) Treated ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Moving Toward a Cure for More Patients With Hodgkin Lymphoma: Expert Guidance and Practical Case Discussions 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Peripheral T-Cell Lymphomas: Contemporary Prognostic and Therapeutic Approaches. 
  Burlington, MA - 5/29/2014
• Prognosis and Treatment of Peripheral T-cell Lymphoma. 
  Boston, MA - 4/12/2014
• Hodgkin Lymphoma. 
  Singapore - 3/30/2014
• Grant opportunities and funding mechanisms for clinical investigators in the field of lymphoma. 
  Scottsdale, AZ - 2/7/2014
• Topic: Hodgkin Lymphoma. 
  Atlanta, GA, 2014; Seattle, WA, 2014 - 2/1/2014
• Translational Analyses of Novel Targeted Agents for the Treatment of Lymphoma. 
  Boston, MA - 1/7/2014
• Survivorship in Hodgkin's Lymphoma: Arterial Disease, Second Cancers, and Other Effects. 
  Boston, MA - 12/13/2013
• Current Therapy for Follicular Lymphoma. 
  Providence, RI - 11/9/2013
• The Prognosis and Treatment of Hodgkin Lymphoma: Current Status and Future Directions. 
  Brooklyn, NY - 10/24/2013
• Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Based on Interim FDG-PET Imaging: Early Results of US Intergroup S0816. 
  Cologne, Italy - 10/1/2013
• Sequential Brentuximab Vedotin (BV) With Adriamycin, Vinblastine, and Dacarbazine (AVD) for Older Patients with Untreated Hodgkin Lymphoma: Preliminary Toxicity Findin... 
  Cologne, Italy - 10/1/2013
• Breakout Session: Emerging New Drugs in Follicular Other Indolent Lymphomas. 
  New York, NY - 9/29/2013
• The Prognosis and Treatment of Hodgkin Lymphoma: Long Term Considerations (i.e., Survivorship). 
  Boston, MA - 9/28/2013
• The Prognosis and Treatment of Hodgkin Lymphoma: Acute and Long-Term Considerations. 
  Dorchester, MA - 9/25/2013
• PET Directed Therapy for Hodgkin Lymphoma: Update on Trials. 
  Houston, TX - 9/20/2013
• Cancer Center Grand Rounds. The Prognosis and Treatment of Hodgkin Lymphoma: Current Status and Future Directions. 
  Boston, MA - 9/13/2013
• Ask the Doctor: Updates on Lymphoma and Treatment Options. 
  Boston, MA - 7/13/2013
• Translational Analysis of Novel Targeted Agents for the Treatment of Lymphoma. 
  North Grafton, MA - 6/25/2013
• State-of-the Art Therapy for PTLD. 
  Seattle, WA - 5/19/2013
• Join now to see all

Other

• Multicenter Analysis of Outcomes of Lymphoma in Pregnancy. 
  Evens AM, The ASCO Post
  http://www.ascopost.com/issues/november-15,-2013/multicenter-analysis-of-outcomes-of-lymphoma-in-pregnancy.aspx
  11/15/2013
• Editor: Advances in the Management of Lymphoma. 
  Evens AM, Highlights from the 12th International Conference on Malignant Lymphoma
  http://www.educationalconcepts.net/online-activity-event.aspx?PUID=15367
  8/1/2013
• Lymphoma Think Tank. 
  Evens AM, Research to Practice
  http://2013researchtopractice.createsend4.com/t/ViewEmail/y/6C47615520E337F6/C2DC492DCE06367514399806BE9B4083
  7/1/2013
• Commentary regarding JCO article that Entecavir May Prevent HBV Reactivation in Rituximab-Treated Lymphoma Patients. 
  Evens AM
  http://www.medscape.com/viewarticle/806777
  6/23/2013
• Interview: Managing Hodgkin Lymphoma. 
  Evens AM, 12th International Conference on Malignant Lymphoma (ICML)
  http://www.managinghodgkinlymphoma.com/about-mhl/contributing-faculty/10-12th-icml-highlights-in-lymphoma/18-hodgkin-lymphoma-in-the-elderly
  6/1/2013
• Virtual poster presentation. A phase II multicenter study of the histone deacetylase inhibitor (HDACi) abexinostat (PCI-24781) in relapsed/refractory follicular lympho... 
  Evens AM, 2012 ASH
  http://www.primeoncology.org/online_education/heme/2012/atl_vp_us.aspx
  Atlanta, GA - 12/10/2012
• Lymphoma. Round Table Discussion. 
  Evens AM, 2012 ASH Update, Sponsor: British Society of Haematology
  http://www.bloodmed-video.com/malignancy/
  Atlanta, GA - 12/9/2012
• Clinical drug trials challenging, rewarding. 
  Evens AM, Worcester Telegram and Gazette
  http://www.telegram.com/article/20120603/NEWS/106039956/0/SEARCH
  6/3/2012
• Hodgkin Lymphoma in Older Patients: Past, Current, and Future Treatment Strategies. Treatment Strategies- Hematology. 
  Evens AM, Cambridge Research Centre. eBook online
  http://viewer.zmags.com/publication/387512a6#/387512a6/1
  1/1/2012
• Research on Treating Lymphoma During Pregnancy. 
  Evens AM, Cancer Network: Home of the Journal Oncology
  http://www.cancernetwork.com/conference-reports/ash2011/content/article/10165/2002762
  12/11/2011
• Rituximab and Liposomal Doxorubicin Improve Progression-Free and Overall Survival When Added to Chemotherapy in Untreated Burkitt's Lymphoma. 
  Evens AM, Monthly Prescribing Reference (MPR)
  http://www.empr.com/rituximab-and-liposomal-doxorubicin-improve-progression-free-and-overall-survival-when-added-to-chemotherapy-in-untreated-burkitts-lymphoma/article/218896/
  12/11/2011
• The Importance of Clinical Trials. 
  Evens AM, University of Massachusetts Medical School
  http://www.youtube.com/watch?v=JNh0t43fBa4
  10/17/2011
• Burkitt’s Lymphoma and Cancer Clinical Trials. 
  Evens AM, Chicago CAN TV21
  http://www.youtube.com/watch?v=oy5I4jSZaXg
  12/10/2010
• ASH Review: Lymphoma. 
  Evens AM, Health Radio Network: Patient Power (radio interview); Healthradionework.com
  12/8/2008
• Breakthroughs in Lymphoma and Other Blood Cancers. 
  Evens AM, Health Radio Network: Patient Power (radio interview); Healthradionework.com
  12/17/2006
• Racial disparities may exist in Hodgkin’s lymphoma. 
  Evens AM, HemOncToday.com.
  http://www.healio.com/hematology-oncology/hematologic-malignancies/news/print/hematology-oncology/%7BF5A392EF-ABB3-42BF-B60B-539C34E017BA%7D/Racial-disparities-may-exist-in-Hodgkins-lymphoma-incidence
• Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin Lymphoma and Non-Hodgkin Lymphoma. 
  Evens AM, Hematologic Oncology Update – Think Tank
• Join now to see all